Business Wire

Flexera Enters Into Definitive Agreement to Acquire Snow Software, Broadening Its Portfolio for Technology Value Optimization

28.11.2023 18:00:00 EET | Business Wire | Press release

Share

Flexera and Snow Software today announced a definitive agreement under which Flexera intends to acquire Snow.

Worldwide IT spending could reach $5.1 trillion in 2024, according to Gartner. It is estimated that up to 32% of this spend is wasted. Together, Flexera and Snow will provide deeper visibility and greater insights into the assets, technologies, terms of licensing and usage that comprise this spend and associated risks. Flexera and Snow will offer an expanded global footprint, a powerful strategic partner network and expanded IT Asset Management (ITAM), SaaS Management and FinOps capabilities. Customers will gain precise, detailed, and dynamic views into their technology blueprint to make strategic business decisions.

Additional value for customers and partners of Snow and Flexera

“This acquisition is a big win for the customers and partners of both companies,” said Jim Ryan, President and CEO of Flexera.

“Flexera and Snow each have different centers of gravity in different subsegments in a broad and dynamic space,” noted Ryan. “Through this acquisition, our people, portfolios and our combined strengths give customers even more choices and an expanded foundation for ITAM and FinOps. The world-class partner network, innovative technology, excellent customer base and talented employees of Snow provide great value to the marketplace. We are excited about the opportunity to grow the value we deliver to customers even further.”

“The combined strengths of Flexera and Snow will help our customers realize the ongoing value of their technology investments,” explained Vishal Rao, President and CEO of Snow. “At Snow, we have been focused on bringing our vision for Technology Intelligence, or the ability to understand and manage all technology, to life. This is a bold proposition, as it both addresses the challenges of today and provides a blueprint to prepare for the future. With this step, we see an incredible opportunity to accelerate Technology Intelligence while complementing Flexera’s mission to help customers derive more value from their technology. Our collective efforts will create further breadth, depth and support for our customers and partners who are adapting to increasingly complex IT environments, while shouldering technical, financial, operational and innovative responsibilities for their organizations. It’s going to be an exciting time, and we look forward to the next phase of our journey with Flexera.”

Continued support for existing products

Flexera will continue to innovate, enhance, maintain, and support both Flexera and Snow solutions. Global partners will have even more support as Flexera will continue to work with partners of both Flexera and Snow, including those that offer hosted options.

The transaction is subject to customary closing conditions, including the receipt of required regulatory approvals. Barclays, Goldman Sachs & Co. LLC, Jefferies LLC, Mizuho Securities USA LLC, and UBS Investment Bank served as financial advisors to Flexera. J.P. Morgan Securities LLC served as financial advisor to Snow.

About Flexera

Flexera saves customers billions of dollars in wasted technology spend. A pioneer in ITAM, Flexera provides award-winning, data-oriented SaaS solutions for technology value optimization (TVO), enabling IT, finance, procurement and cloud teams to gain deep insights into cost optimization, compliance and risks for each business service. Flexera One solutions are built on a set of definitive customer, supplier and industry data, powered by Technopedia, that enables organizations to visualize their Enterprise Technology Blueprint™. Thousands of customers subscribe to Flexera’s technology value optimization solutions, delivered by 1,300+ team members worldwide. Learn more at www.flexera.com.

About Snow Software

Snow Software is changing the way organizations understand and manage their technology consumption. Snow’s technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility. Learn more at www.snowsoftware.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Flexera PR Contact:

Cyndi Tackett
Flexera
publicrelations@flexera.com

Snow Software PR Contact:

Ciri Haugh
Snow Software
press@snowsoftware.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye